Endo ERN
Find an expert
Ukraine
Endo ERN
Search
  • Rare Endocrine Conditions

    Endocrine Conditions

    Endo-ERN is focused on 8 main thematic groups (MTGs) which cover rare and/or complex endocrine conditions

    Go to overview

    Categories

    • MTG1Adrenal
    • MTG2Disorders of Calcium & Phosphate Homeostasis
    • MTG3Genetic Disorders of Glucose & Insulin Homeostasis
    • MTG4Genetic Endocrine Tumour Syndromes
    • MTG5Growth & Genetic Obesity Syndromes
    • MTG6Hypothalamic and Pituitary Conditions
    • MTG7Sex Development & Maturation
    • MTG8Thyroid
  • About Us

    About Us

    Endo-ERN is a network of 100+ Reference Centres (RCs) in 27 EU member states+Norway that offers access to clinical experts for patients with rare endocrine conditions.  

    Go to overview

    Who we are

    • About Endo-ERN
    • What we do
    • Reference centres
    • Work packages
    • Project team

    Information

    • Events
    • FAQ
    • Newsletter
    • Contact
    • ERNs
  • For Professionals

    For Professionals

    Endo-ERN is the network for rare endocrine conditions providing healthcare professionals with access to a variety of resources to support patient care.  

    Our Network

    • About Endo-ERN
    • Find a Reference Centre

    Research

    • Registries
    • Publications
    • Clinical Trials

    Support Tools

    • Virtual Consultations
    • Guidelines
    • COVID-19

    Training & Education

    • Webinars
    • Exchange Programme
  • For Members

    For Members

    If you work at a member institution this page will help with your Endo-ERN contributions.  

    Go to overview

    Quick Links

    • Cite Endo-ERN
    • CPMS 2.0
    • GA2026
    • The Journal

    Evaluation

    • Continuous Monitoring Exercise
    • 5-year evaluation
    • HCP Performance System

    Network Participation

    • Event Endorsement
    • Member Survey
    • Webinar Planning
    • MTG Representatives

    Membership Management

    • Update Member Contacts
    • Request Disease Area Expansion
    • Termination Policy
  • For Patients

    For Patients

    Access to rare disease expertise without the need to travel is a core ERN objective.  Our ePAGs contribute to all Endo-ERN activities.  

    Go to overview

    Patient information

    • What are European Reference Networks?
    • Cross-border healthcare
    • Rare endocrine conditions
    • Patient materials

    ePAG information

    • European Patient Advocacy Groups
    • Patient representatives
    • How to become an Endo-ERN ePAG
  • Search
  • Rare Endocrine Conditions
  • About Us
  • For Professionals
  • For Members
  • For Patients
  • Search
  • Rare Endocrine Conditions
  • About Us
  • For Professionals
  • For Members
  • For Patients
  • Search
Endo ERN
Ukraine
Find an expert
Search
/ Publications Overview / Publications Database

Endo-ERN Publications Database

RDD IssuesBack to Publications Overview

Filter list of publications

940 publication(s) found matching the search criteria

Reiterative infusions of MSCs improve pediatric osteogenesis imperfecta eliciting a pro‐osteogenic paracrine response: TERCELOI clinical trial


Author(s): Infante A, Gener B, Vázquez M, Olivares N, Arrieta A, Grau G, Llano I, Madero L, Bueno AM, Sagastizabal B, Gerovska D, Araúzo‐Bravo MJ, Astigarraga I, Rodríguez CI
Affiliated Institution / ERN: ERN BOND ;
Condition / Disease: Osteogenesis imperfecta
Publication: Clinical and Translational Medicine v11.1 Year: 2021 ORPHAcode / other: ORPHA666
DOI: 10.1002/ctm2.265 Keywords: cell therapy,mesenchymal stem cell,paracrine mechanism of action,regenerative medicine

The Efficacy and Short- and Long-Term Side Effects of Radioactive Iodine Treatment in Pediatric Graves’ Disease: A Systematic Review


Author(s): Lutterman SL, Zwaveling-Soonawala N, Verberne HJ, Verburg FA, van Trotsenburg AP, Mooij CF
Affiliated Institution / ERN: Amsterdam UMC ; Erasmus MC: University Medical Center Rotterdam ;
Condition / Disease: Paediatric-onset Graves disease
Publication: European Thyroid Journal v10.5 p353-363 Year: 2021 ORPHAcode / other: ORPHA525731
DOI: 10.1159/000517174 Keywords: Graves' disease,Pediatric Graves' disease,Radioactive iodine,Side effects
MTG8

Thyroid Dysfunction and Thyroid Cancer in Childhood Cancer Survivors: Prevalence, Surveillance and Management


Author(s): Lebbink C, Waguespack S, van Santen H
Affiliated Institution / ERN: University Medical Center Utrecht ;
Condition / Disease: Thyroid carcinoma
Publication: Frontiers of Hormone Research p140-153 Year: 2021 ORPHAcode / other: ORPHA100088
DOI: 10.1159/000513805 Keywords:
MTG8

Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome: Data from the PATRO Children Study


Author(s): Backeljauw P, Kanumakala S, Loche S, Schwab KO, Pfäffle RW, Höybye C, Lundberg E, Battelino T, Kriström B, Giemza T, Zouater H
Affiliated Institution / ERN: Karolinska University Hospital ; University Medical Centre Ljubljana ;
Condition / Disease: 45,X
Publication: Hormone Research in Paediatrics v94.3-4 p133-143 Year: 2021 ORPHAcode / other: ORPHA881
DOI: 10.1159/000515875 Keywords: Growth hormone replacement therapy,PATRO Children,Pediatric endocrinology,Turner syndrome
MTG7

Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages


Author(s): Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, Beintker M, Beyersdorff D, Bokemeyer C, Busch J, Classen J, de Wit M, Dieckmann K, Diemer T, Dieing A, Gockel M, Göckel-Beining B, Hakenberg OW, Heidenreich A, Heinzelbecker J, Herkommer K, Hermanns T, Kaufmann S, Kornmann M, Kotzerke J, Krege S, Kristiansen G, Lorch A, Müller A, Oechsle K, Ohloff T, Oing C, Otto U, Pfister D, Pichler R, Recken H, Rick O, Rudolph Y, Ruf C, Schirren J, Schmelz H, Schmidberger H, Schrader M, Schweyer S, Seeling S, Souchon R, Winter C, Wittekind C, Zengerling F, Zermann D, Zillmann R, Albers P
Affiliated Institution / ERN: ERN BOND ;
Condition / Disease: Germ Cell Tumours of the Testis
Publication: Urologia Internationalis v105.3-4 p169-180 Year: 2021 ORPHAcode / other:
DOI: 10.1159/000510407 Keywords: Clinical practice guideline,Diagnosis,Fertility preservation,Germ cell tumour of the testis,Prognosis,Staging

Papillary thyroid carcinoma arising in ectopic thyroid tissue within sternocleidomastoid muscle: a review of current literature


Author(s): BARREA L, FONDERICO F, DI SOMMA C, PUGLIESE G, DE ALTERIIS G, MASCOLO M, COLAO A, SAVASTANO S
Affiliated Institution / ERN:
Condition / Disease:
Publication: Minerva Endocrinologica v45.4 Year: 2021 ORPHAcode / other:
DOI: 10.23736/S0391-1977.20.03167-3 Keywords:

Somatostatin receptor ligands induce TSH deficiency in thyrotropin-secreting pituitary adenoma


Author(s): Illouz F, Chanson P, Sonnet E, Brue T, Ferriere A, Raffin Sanson M, Vantyghem M, Raverot G, Munier M, Rodien P, Briet C
Affiliated Institution / ERN: CHU d'Angers ; Assistance Publique-Hôpitaux de Marseille ; Hospices Civils de Lyon ;
Condition / Disease: TSH-secreting pituitary adenoma
Publication: European Journal of Endocrinology v184.1 p1-8 Year: 2021 ORPHAcode / other: ORPHA91347
DOI: 10.1530/EJE-20-0484 Keywords:
MTG6

A novel peptide antagonist of the human growth hormone receptor


Author(s): Basu R, Nahar K, Kulkarni P, Kerekes O, Sattler M, Hall Z, Neggers S, Holub JM, Kopchick JJ
Affiliated Institution / ERN: Erasmus MC: University Medical Center Rotterdam ;
Condition / Disease:
Publication: Journal of Biological Chemistry v296 p100588 Year: 2021 ORPHAcode / other:
DOI: 10.1016/j.jbc.2021.100588 Keywords: GH receptor,growth hormone,peptide antagonist,peptide mimetic,site 1-binding helix

Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks


Author(s): Fanciulli G, Di Molfetta S, Dotto A, Florio T, Feola T, Rubino M, de Cicco F, Colao A, Faggiano A
Affiliated Institution / ERN: IRCCS Ospedale Policlinico San Martino – Genova ; IRCCS Auxologico Italian Institute - Milan ; AOU Federico II - Naples ;
Condition / Disease: Pheochromocytoma and Paraganglioma
Publication: Journal of Clinical Medicine v10.1 p88 Year: 2020 ORPHAcode / other: ORPHA573163
DOI: 10.3390/jcm10010088 Keywords: atezolizumab,avelumab,cemiplimab,durvalumab,immune checkpoint inhibitors,ipilimumab,nivolumab,paraganglioma,pembrolizumab,pheochromocytoma
MTG4

Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead


Author(s): Colao A, de Nigris F, Modica R, Napoli C
Affiliated Institution / ERN: National Institute of Children's Diseases ; Máxima Medisch Centrum Veldhoven ;
Condition / Disease: Neuroendocrine Neoplasm
Publication: Frontiers in Endocrinology v11 Year: 2020 ORPHAcode / other: ORPHA877
DOI: 10.3389/fendo.2020.604341 Keywords: biomarkers,epigenetics,neuroendocrine,neuroendocrine neoplasms,neuroendocrine tumor,trials

Medical Treatment of Cushing’s Disease: An Overview of the Current and Recent Clinical Trials


Author(s): Pivonello R, Ferrigno R, De Martino MC, Simeoli C, Di Paola N, Pivonello C, Barba L, Negri M, De Angelis C, Colao A
Affiliated Institution / ERN: AOU Federico II - Naples ;
Condition / Disease: Cushing disease
Publication: Frontiers in Endocrinology v11 Year: 2020 ORPHAcode / other: ORPHA96253
DOI: 10.3389/fendo.2020.00648 Keywords: ACTH,Cushing's disease,clinical trials,cortisol,experimental therapy,hypercortisolism,pituitary tumor
MTG6

Hair cortisol-a method to detect chronic cortisol levels in patients with Prader-Willi syndrome


Author(s): Shukur HH, de Rijke YB, van Rossum EFC, Hussain-Alkhateeb L, Höybye C
Affiliated Institution / ERN:
Condition / Disease: Prader-Willi syndrome
Publication: BMC Endocrine Disorders v20.1 Year: 2020 ORPHAcode / other: ORPHA739
DOI: 10.1186/s12902-020-00646-w Keywords: Chronic stress,Hair cortisol,Obesity,Prader-Willi syndrome
MTG5

Multidisciplinary management of acromegaly: A consensus


Author(s): Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen KCJ, Zatelli MC, Melmed S
Affiliated Institution / ERN:
Condition / Disease: Acromegaly
Publication: Reviews in Endocrine and Metabolic Disorders v21.4 p667-678 Year: 2020 ORPHAcode / other: ORPHA963
DOI: 10.1007/s11154-020-09588-z Keywords: Acromegaly,Consensus,Medical therapy,Multidisciplinary management,Pituitary tumor centers of excellence,Radiotherapy,Surgery
MTG6

Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data


Author(s): Riccio E, Zanfardino M, Ferreri L, Santoro C, Cocozza S, Capuano I, Imbriaco M, Feriozzi S, Pisani A, Pisani A, Riccio E, Cocozza S, Santoro C, Esposito R, Imbriaco M, Russo C, Di Risi T, Chiariotti L, Spinelli L, Pontillo A, Cuocolo A, Cennamo G, Colao A
Affiliated Institution / ERN: ERN BOND ;
Condition / Disease: Fabry disease
Publication: European Journal of Human Genetics v28.12 p1662-1668 Year: 2020 ORPHAcode / other: ORPHA:324
DOI: 10.1038/s41431-020-0677-x Keywords:

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly


Author(s): Gadelha MR, Gu F, Bronstein MD, Brue TC, Fleseriu M, Shimon I, van der Lely AJ, Ravichandran S, Kandra A, Pedroncelli AM, Colao AAL
Affiliated Institution / ERN:
Condition / Disease: Acromegaly
Publication: Endocrine Connections v9.12 p1178-1190 Year: 2020 ORPHAcode / other: ORPHA963
DOI: 10.1530/EC-20-0361 Keywords: acromegaly,diabetes mellitus,hyperglycemia,pasireotide
MTG6

Reference ranges of late-night salivary cortisol and cortisone measured by LC–MS/MS and accuracy for the diagnosis of Cushing’s syndrome


Author(s): Ponzetto F, Settanni F, Parasiliti-Caprino M, Rumbolo F, Nonnato A, Ricciardo M, Amante E, Priolo G, Vitali S, Anfossi L, Arvat E, Ghigo E, Giordano R, Mengozzi G
Affiliated Institution / ERN:
Condition / Disease: Cushing’s Syndrome
Publication: Journal of Endocrinological Investigation v43.12 p1797-1806 Year: 2020 ORPHAcode / other: ORPHA553
DOI: 10.1007/s40618-020-01388-1 Keywords: Cortisol,Cortisone,Cushing’s syndrome,Hypercortisolism,LC–MS/MS,Saliva
MTG1 MTG6

Genotype-phenotype correlations in children and adolescents with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency


Author(s): Dörr H, Schulze N, Bettendorf M, Binder G, Bonfig W, Denzer C, Dunstheimer D, Salzgeber K, Schmidt H, Schwab KO, Voss E, Wabitsch M, Wölfle J
Affiliated Institution / ERN:
Condition / Disease: Congenital Adrenal Hyperplasia
Publication: Molecular and Cellular Pediatrics v7.1 Year: 2020 ORPHAcode / other: ORPHA418
DOI: 10.1186/s40348-020-00100-w Keywords: 17OHP,21-Hydroxylase deficiency,ACTH stimulation test,Androgenisation,CYP21A2 mutations,Premature pubarche
MTG7

The extent of surgery for low-risk 1–4 cm papillary thyroid carcinoma: a catch-22 situation. A retrospective analysis of 497 patients based on the 2015 ATA Guidelines recommendation 35


Author(s): Anda Apiñániz E, Zafon C, Ruiz Rey I, Perdomo C, Pineda J, Alcalde J, García Goñi M, Galofré JC
Affiliated Institution / ERN:
Condition / Disease: Follicular thyroid carcinoma
Publication: Endocrine v70.3 p538-543 Year: 2020 ORPHAcode / other: ORPHA146
DOI: 10.1007/s12020-020-02371-9 Keywords: Initial Management,Lobectomy,Low Risk,Papillary Thyroid Carcinoma,Risk Factors,Total Thyriodectomy
MTG8

Significance of nuclear cathepsin V in normal thyroid epithelial and carcinoma cells


Author(s): Al-Hashimi A, Venugopalan V, Sereesongsaeng N, Tedelind S, Pinzaru AM, Hein Z, Springer S, Weber E, Führer D, Scott CJ, Burden RE, Brix K
Affiliated Institution / ERN:
Condition / Disease: Thyroid Carcinoma
Publication: Biochimica et Biophysica Acta (BBA) - Molecular Cell Research v1867.12 p118846 Year: 2020 ORPHAcode / other: ORPHA100088
DOI: 10.1016/j.bbamcr.2020.118846 Keywords: Cysteine cathepsins,Non-canonical trafficking,Nuclear forms,Proliferation-promoting,Thyroid cancer
MTG8

Enfermedad de Graves con autoanticuerpos contra el receptor de la TSH negativos: a propósito de 5 casos


Author(s): Scatti Regàs A, Pujol Borrell R, Ferrer Costa R, Puerto Carranza E, Clemente León M
Affiliated Institution / ERN:
Condition / Disease: Paediatric-onset Graves disease
Publication: Anales de Pediatría v93.6 p417-419 Year: 2020 ORPHAcode / other: ORPHA525731
DOI: 10.1016/j.anpedi.2020.01.008 Keywords:
MTG8

ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus


Author(s): Giannetta E, Guarnotta V, Altieri B, Sciammarella C, Guadagno E, Malandrino P, Puliani G, Feola T, Isidori AM, Colao AAL, Faggiano A
Affiliated Institution / ERN: AOUI Verona ; AOU Federico II - Naples ; ERN BOND ;
Condition / Disease: Neuroendocrine Neoplasm
Publication: European Journal of Endocrinology v183.6 pR197-R215 Year: 2020 ORPHAcode / other: ORPHA877
DOI: 10.1530/EJE-20-0506 Keywords:
MTG8

The optimal numerosity of the referral population of pituitary tumors centers of excellence (PTCOE): A surgical perspective


Author(s): Mortini P, Nocera G, Roncelli F, Losa M, Formenti AM, Giustina A
Affiliated Institution / ERN:
Condition / Disease: Pituitary adenoma
Publication: Reviews in Endocrine and Metabolic Disorders v21.4 p527-536 Year: 2020 ORPHAcode / other: ORPHA99408
DOI: 10.1007/s11154-020-09564-7 Keywords: Learning curve,Pituitary adenomas,Pituitary surgery,Pituitary tumor center of excellence
MTG6

Etiology and Pathophysiology of Hypoparathyroidism: A Narrative Review


Author(s): Pasieka JL, Wentworth K, Yeo CT, Cremers S, Dempster D, Fukumoto S, Goswami R, Houillier P, Levine MA, Pasternak JD, Perrier ND, Sitges-Serra A, Shoback DM
Affiliated Institution / ERN: Reference centre for rare diseases of calcium and phosphate-HEGP ;
Condition / Disease: Hypoparathyroidism
Publication: Journal of Bone and Mineral Research v37.12 p2586-2601 Year: 2020 ORPHAcode / other: ORPHA181405
DOI: 10.1002/jbmr.4714 Keywords: CELL/TISSUE SIGNALING,DISORDERS OF CALCIUM/PHOSPHATE METABOLISM,ENDOCRINE PATHWAYS,HORMONE REPLACEMENT/RECEPTOR MODULATORS,PARATHYROID-RELATED DISORDERS,PTH/VIT D/FGF23,THERAPEUTICS
MTG2

Early-Onset Osteoporosis: Rare Monogenic Forms Elucidate the Complexity of Disease Pathogenesis Beyond Type I Collagen


Author(s): Costantini A, Mäkitie RE, Hartmann MA, Fratzl-Zelman N, Zillikens MC, Kornak U, Søe K, Mäkitie O
Affiliated Institution / ERN: Erasmus MC: University Medical Center Rotterdam ; ERN BOND ;
Condition / Disease:
Publication: Journal of Bone and Mineral Research v37.9 p1623-1641 Year: 2020 ORPHAcode / other:
DOI: 10.1002/jbmr.4668 Keywords: BONE HISTOMORPHOMETRY,BONE MODELING AND REMODELING,GENETIC RESEARCH,OSTEOPOROSIS,WNT/β-CATENIN/LRPS

Comaneci-Assisted Coiling as a Treatment Option for Acutely Ruptured Wide Neck Cerebral Aneurysm: Case Series of 118 Patients


Author(s): Sirakov A, Minkin K, Penkov M, Ninov K, Karakostov V, Sirakov S
Affiliated Institution / ERN:
Condition / Disease:
Publication: Neurosurgery v87.6 p1148-1156 Year: 2020 ORPHAcode / other:
DOI: 10.1093/neuros/nyaa200 Keywords: Bifurcation aneurysms,Coil embolization,Comaneci device,Endovascular remodeling,Wide-necked aneurysms

Imbalanced cortisol concentrations in glycogen storage disease type I: evidence for a possible link between endocrine regulation and metabolic derangement


Author(s): Rossi A, Simeoli C, Salerno M, Ferrigno R, Della Casa R, Colao A, Strisciuglio P, Parenti G, Pivonello R, Melis D
Affiliated Institution / ERN:
Condition / Disease:
Publication: Orphanet Journal of Rare Diseases v15.1 Year: 2020 ORPHAcode / other:
DOI: 10.1186/s13023-020-01377-w Keywords: 11βHSD1,Autoimmune,Cholesterol,Cortisol,Insulin-resistance

Providing high-quality care remotely to patients with rare bone diseases during COVID-19 pandemic


Author(s): Brizola E, Adami G, Baroncelli GI, Bedeschi MF, Berardi P, Boero S, Brandi ML, Casareto L, Castagnola E, Fraschini P, Gatti D, Giannini S, Gonfiantini MV, Landoni V, Magrelli A, Mantovani G, Michelis MB, Nasto LA, Panzeri L, Pianigiani E, Scopinaro A, Trespidi L, Vianello A, Zampino G, Sangiorgi L
Affiliated Institution / ERN: ERN BOND ; AOU-Bologna ; AOUI Verona ; AOU Pisan ; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan ; IRCCS Istituto Giannina Gaslini, Genova ; University Hospital of Padova ;
Condition / Disease: Rare bone disease
Publication: Orphanet Journal of Rare Diseases v15.1 Year: 2020 ORPHAcode / other: ORPHA93419
DOI: 10.1186/s13023-020-01513-6 Keywords: 2019-nCoV,Bone diseases,COVID-19,Care,Coronavirus,ERN,Rare diseases,Remote

Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study


Author(s): Perros P, Žarković MP, Panagiotou GC, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L, Boschi AM, Nardi M, Brix TH, Covelli D, Daumerie C, Eckstein AK, Fichter N, Ćirić S, Hegedüs L, Kahaly GJ, Konuk O, Lareida JJ, Okosieme OE, Leo M, Mathiopoulou L, Clarke L, Menconi F, Morris DS, Orgiazzi J, Pitz S, Salvi M, Muller I, Knežević M, Wiersinga WM, Currò N, Dayan CM, Marcocci C, Marinò M, Möller L, Pearce SH, Törüner F, Bernard M
Affiliated Institution / ERN:
Condition / Disease: Graves disease
Publication: Journal of Endocrinological Investigation v43.12 p1717-1722 Year: 2020 ORPHAcode / other: E05.0
DOI: 10.1007/s40618-020-01258-w Keywords: Asymmetric,Graves’,Orbitopathy,Thyroid,Unilateral
MTG8

Safety of current recombinant human growth hormone treatments for adults with growth hormone deficiency and unmet needs


Author(s): Höybye C, Beck-Peccoz P, Simsek S, Zabransky M, Zouater H, Stalla G, Murray RD
Affiliated Institution / ERN:
Condition / Disease: Growth Hormone Deficiency
Publication: Expert Opinion on Drug Safety v19.12 p1539-1548 Year: 2020 ORPHAcode / other: ORPHA101957
DOI: 10.1080/14740338.2020.1839410 Keywords: Growth hormone,adults,growth hormone replacement,safety
MTG6

Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications


Author(s): Fanciulli G, Ruggeri RM, Grossrubatscher E, Calzo FL, Wood TD, Faggiano A, Isidori A, Colao A
Affiliated Institution / ERN: ERN BOND ;
Condition / Disease: Carcinoid syndrome
Publication: Reviews in Endocrine and Metabolic Disorders v21.4 p599-612 Year: 2020 ORPHAcode / other: ORPHA100093
DOI: 10.1007/s11154-020-09547-8 Keywords: Analytical methods,Carcinoid syndrome,Neuroendocrine neoplasm,Serotonin pathway,Telotristat
Page 25 of 32« First«...1020...2324252627...30...»Last »

Endo-ERN Newsletter

Subscribe to our newsletter to receive updates on all network activities and new resources. As soon as you subscribe you will receive an email asking you to confirm your registration.

SIGN UP NOW

News

  • All news
  • Newsletter signup

Events

  • Upcoming events
  • Webinars

Information

  • About Us
  • Contact
  • FAQs

Social Links

Linkedin Facebook Youtube

Contact

Endo-ERN
Coordinating Center
Meibergdreef 9
1105 AZ AMSTERDAM
The Netherlands

info@endo-ern.eu
Funded by the European Union
©2026. All Rights Reserved. Endo-ERN

Privacy Policy – GDPR

Website design by Elan Creative

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Information video for patients and healthcare professionals

Type and Press “enter” to Search

Search
Privacy Overview
Endo-ERN

Endo-ERN Privacy Policy

Endo-ERN is committed to user’s privacy and does not track personal data when visiting our website. We act in accordance with Regulation 2016/679 of the European Parliament and of the Council.

‘Personal data’ means any information relating to an identified or identifiable natural person. An identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as:

  • a name
  • an identification number
  • location data
  • an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person

Cookies

Endo-ERN only tracks anonymised data for statistical purposes. We do this via analytical cookies, placed through an anonymous IP Google analytics tag. The purpose of these cookies are to track the efficiency and success of the website.

These cookies do not store any personal data that can be linked to a natural person, but may save data such as inter alia, data about the website from which a person has come (the so-called referrer), which sub-pages were visited, or how often and for what duration a sub-page was viewed. The data collected through this is general data only, and cannot be traced back to one person.

It is possible to prevent the setting of cookies, by means of a setting of the Internet browser used. On top of that, already set cookies may be deleted at any time via an Internet browser or other software programs. This is possible in all popular Internet browsers.

Google Analytics does not share any data with third parties.

The principles of data protection do not apply to anonymous information and because these cookies minimally impact the privacy of the user, it is not necessary to ask for permission to use these cookies.

Newsletter

You may always unsubscribe from our newsletter at any time through the unsubscribe button located in our newsletter. Endo-ERN is both the controller and responsible for processing of any data regarding the newsletter. Endo-ERN does not make use of a third party for the Newsletter service.

E-services

Endo-ERN has a contact form, which activates your email software and allows you to send a comment or question to a general email address. When you send such a message, your personal data is collected only to the extent necessary to reply. If the team responsible for the mailbox is unable to answer your question, or your questions has regards to another party, it might forward your email to another service.

If you have any questions about the processing of your email and related personal data, do not hesitate to include them in your message.

The collected personal data and all information related to the above mentioned consultation is stored on the email server of the Endo-ERN Coordinating office and potentially those who have been concerned in the correspondence in order to respond to your comment.

Newsletter Tracking

The Endo-ERN newsletter makes use of tracking in order to be able to conduct a statistical analysis of the success or failure of online marketing campaigns. Endo-ERN may see if an email containing a newsletter was opened by a user, when it was opened, and which links were opened. 
The data collected through this tracking is generated and stored by Endo-ERN and is not shared with third parties, but may be used to adapt future content of newsletters in order to better meet the interests of our subscribers.

Contact details

For any questions regarding our privacy policy, please contact the Endo-ERN coordinating office.

You have the right to be forgotten and removed completely from the Endo-ERN contact database. To request this, please contact the Endo-ERN coordinating office.

Endo-ERN Coordinating Center, Meibergdreef 9, 1105 AZ  AMSTERDAM. The Netherlands

 info@endo-ern.eu
Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Powered by  GDPR Cookie Compliance